Table 4.
Results for rate of force development, kf,dev, at maximal pCa 4.8 and submaximal pCa 5.75
| kf,dev (s-1) at pCa 4.8 | NTGβ | NTGβ,PKA | t/tβ | t/tβ,PKA | ANOVA |
|---|---|---|---|---|---|
| n | 9 | 8 | 10 | 10 | |
| Pi (mM) = 0 | 5.59 ± 0.24 | 6.12 ± 0.39 | 6.69 ± 0.41 | 6.37 ± 0.21 | Main Effects |
| 1 | 5.37 ± 0.37 | 6.45 ± 0.25 | 6.80 ± 0.43 | 7.57 ± 0.41 | MYBPC3, †Pi, *PKA |
| 2 | 5.98 ± 0.41 | 6.75 ± 0.27 | 7.19 ± 0.42 | 8.22 ± 0.53 | |
| 3 | 6.02 ± 0.44 | 7.12 ± 0.33 | 7.84 ± 0.41 | 9.08 ± 0.48 | Interactions |
| 4 | 6.69 ± 0.70 | 7.45 ± 0.31 | 8.20 ± 0.50 | 9.62 ± 0.58 | Pi × MYBPC3 |
| 5 | 6.94 ± 0.31 | 8.07 ± 0.46 | 8.87 ± 0.51 | 9.91 ± 0.48 | *Pi × PKA × MYBPC3 |
| 8 | 7.51 ± 0.44 | 8.23 ± 0.38 | 9.60 ± 0.50 | 10.67 ± 0.66 | |
| 12 | 8.42 ± 0.61 | 8.09 ± 0.27 | 9.82 ± 0.49 | 11.52 ± 0.59 | |
| Δkf,dev/ΔPi | 0.33 ± 0.07 | 0.40 ± 0.05 | 0.52 ± 0.06 | 0.68 ± 0.05 | †MYBPC3, *PKA |
| kf,dev (s-1) at pCa 5.75 | |||||
| Pi (mM) = 0 | 5.48 ± 0.24 | 6.10 ± 0.42 | 6.30 ± 0.39 | 6.48 ± 0.37 | Main effects |
| 1 | 5.90 ± 0.30 | 6.36 ± 0.44 | 6.93 ± 0.40 | 6.81 ± 0.71 | †MYBPC3, †Pi |
| 2 | 6.78 ± 0.53 | 6.36 ± 0.24 | 7.50 ± 0.36 | 8.38 ± 0.59 | |
| 3 | 6.81 ± 0.35 | 7.09 ± 0.36 | 7.80 ± 0.42 | 8.60 ± 0.48 | |
| 4 | 7.28 ± 0.20 | 7.38 ± 0.20 | 8.22 ± 0.36 | 9.05 ± 0.81 | |
| 5 | 7.53 ± 0.28 | 7.98 ± 0.44 | 8.80 ± 0.47 | 9.10 ± 0.45 | |
| 8 | 8.48 ± 0.51 | 8.24 ± 0.63 | 9.83 ± 0.62 | 10.10 ± 0.45 | |
| 12 | 8.69 ± 0.31 | 7.93 ± 0.57 | 9.67 ± 0.50 | 10.51 ± 0.98 | |
| Δkf,dev/ΔPi | 0.39 ± 0.03 | 0.23 ± 0.10 | 0.48 ± 0.04 | 0.64 ± 0.07 | †MYBPC3 *PKA × MYBPC3 |
Values are means ± SE; n, number of strips. The sensitivity of kf,dev to Pi, Δkf,dev/ΔPi, was calculated as the slope by linear regression using values measured at 0–5 mM Pi. Statistical results reflect repeated-measures ANOVA. Two-way ANOVA was then applied to Δkf,dev/ΔPi. *P < 0.05, †P < 0.01. NTGβ, nontransgenic; t/tβ, transgenic lacking cMyBP-C; PKA, protein kinase A.